Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy
about
Radiographic contrast-media-induced acute kidney injury: pathophysiology and prophylactic strategiesContrast-induced nephropathy in interventional cardiologyRemote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option?Contemporary management of infrapopliteal peripheral arterial disease.The risk of acute radiocontrast-mediated kidney injury following endovascular therapy for acute ischemic stroke is low.
P2860
Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rationale, design, and baselin ...... f contrast-induced nephropathy
@en
Rationale, design, and baselin ...... contrast-induced nephropathy.
@nl
type
label
Rationale, design, and baselin ...... f contrast-induced nephropathy
@en
Rationale, design, and baselin ...... contrast-induced nephropathy.
@nl
prefLabel
Rationale, design, and baselin ...... f contrast-induced nephropathy
@en
Rationale, design, and baselin ...... contrast-induced nephropathy.
@nl
P2860
P356
P1433
P1476
Rationale, design, and baselin ...... f contrast-induced nephropathy
@en
P2093
ACT Trial Investigators
P2860
P2888
P356
10.1186/1745-6215-10-38
P577
2009-06-04T00:00:00Z